证券日报网讯 中源协和9月26日在互动平台回答投资者提问时表示，公司参股的北京三有利公司与首都 医科大学共同申报的"人牙髓间充质干细胞注射液"治疗慢性牙周炎于2024年完成Ⅱ期临床全部受试者入 组，正在开展定期随访工作。治疗特发性肺纤维化适应症完成Ⅰ期所有受试者给药，正开展临床安全 性、有效性数据整理。 （编辑 任世碧） ...

证券代码：600645 证券简称：中源协和 公告编号：2025-038 中源协和细胞基因工程股份有限公司 关于用于现金管理的闲置募集资金归还至募集资金 专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2024 年 12 月 18 日召开十一届十五次临时董事会和十一届七次临时 监事会，会议审议通过了《关于使用暂时闲置募集资金及自有资金进行现金管理 的议案》。在不影响正常经营、不影响募集资金项目建设和募集资金使用计划的 前提下，同意公司及控股子公司使用不超过人民币 1.2 亿元的闲置募集资金及不 超过人民币 6 亿元的闲置自有资金进行现金管理，自公司董事会、监事会审议通 过之日起 12 个月内有效。具体详见公司公告：2024-051、052、053。 后公司使用 1.2 亿闲置募集资金购买了华夏银行股份有限公司上海分行人 民币单位结构性存款 DWJGX2510630，产品期限 90 天，成立日 2025 年 6 月 27 日， 到期日 2025 年 9 月 25 日（具体详见公司公告：2025-026）。该产品 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600645 证券简称：中源协和 公告编号：2025-037 中源协和细胞基因工程股份有限公司 关于全资子公司获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 药品名称：VUM02注射液 剂型：注射剂 规格：5E7个细胞（10 mL）/袋 注册分类：治疗用生物制品1类 申请事项：境内生产药品注册临床试验 申请人：武汉光谷中源药业有限公司 受理号：CXSL2500507 通知书编号：2025LP02332 审批结论： 中源协和细胞基因工程股份有限公司（以下简称"公司"）全资子公司武汉光谷中源药业有限公司于2025 年9月9日收到国家药品监督管理局核准签发的关于VUM02注射液用于治疗重型/危重型肺炎的《药物临 床试验批准通知书》。现对有关信息公告如下： 一、药品基本信息 根据《中华人民共和国药品管理法》及有关规定，经审查，2025年6月23日受理的VUM02注射液符合药 品注册的有关要求，同意开展重型/危重型肺炎的临床试验。 申请人提交的 ...

Group 1 - The core point of the article is that Zhongyuan Union has received approval for clinical trials of VUM02 injection for the treatment of severe/critical pneumonia from the National Medical Products Administration [2] Group 2 - The approval was granted to Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhongyuan Union [2] - The approval notification was issued on September 9, 2025 [2]

Group 1 - The core point of the article is that Zhongyuan Qihua has received approval from the National Medical Products Administration for its VUM02 injection to treat severe/critical pneumonia, which could enhance its market position and revenue potential [1] - Zhongyuan Qihua's revenue composition for the first half of 2025 shows that manufacturing accounts for 68.9%, services for 28.3%, and other businesses for 2.79% [1] - As of the report, Zhongyuan Qihua has a market capitalization of 11.6 billion yuan [1]

证券代码：600645 证券简称：中源协和 公告编号：2025-037 中源协和细胞基因工程股份有限公司 关于全资子公司获得药物临床试验批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）全资子公司武汉 光谷中源药业有限公司于 2025 年 9 月 9 日收到国家药品监督管理局核准签发的 关于 VUM02 注射液用于治疗重型/危重型肺炎的《药物临床试验批准通知书》。 现对有关信息公告如下： 一、药品基本信息 药品名称：VUM02 注射液 剂型：注射剂 受理号：CXSL2500507 通知书编号：2025LP02332 审批结论： 根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 6 月 23 日受理的 VUM02 注射液符合药品注册的有关要求，同意开展重型/危重型肺炎的 临床试验。 申请人提交的临床试验方案名称：一项以标准疗法为基础治疗评价 VUM02 注射液治疗重型/危重型肺炎患者的有效性和安全性的多中心、随机、双盲、安 慰剂对照的Ⅱ/Ⅲ期临 ...

Core Viewpoint - The company Zhongyuan Xiehe has received approval from the National Medical Products Administration for clinical trials of VUM02 injection for the treatment of severe/critical pneumonia, marking a significant step in the development of a novel cell therapy product [1] Company Summary - The full subsidiary Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd. has been granted a "Drug Clinical Trial Approval Notice" for VUM02 injection [1] - VUM02 injection is derived from umbilical cord mesenchymal stem cells (UC-MSC) obtained from selected healthy newborns, indicating a unique source for the new drug [1] - The total research and development investment for the related project amounts to RMB 16.5624 million [1] Industry Summary - Currently, there are no similar cell therapies approved for the treatment of severe/critical pneumonia globally, highlighting a potential market opportunity for VUM02 injection [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia, marking a significant advancement in the company's product pipeline [1] Company Summary - VUM02 injection is a cryopreserved cell preparation independently developed by Zhongyuan Union, with the clinical indication expanding to include the treatment of severe/critical pneumonia [1] - As of the announcement date, there are no similar cell drugs approved for the treatment of severe/critical pneumonia globally, with the fastest progressing similar drugs still in clinical trial stages [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is an innovative drug developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSC) [1] - The drug is a cryopreserved cell preparation made from selected healthy newborn umbilical cord tissue, which undergoes in vitro separation, expansion, harvesting, and freezing [1] - The clinical trial aims to expand the indications for VUM02 injection to include the treatment of severe/critical pneumonia [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is an autologous developed cryopreserved cell preparation derived from selected healthy newborn umbilical cord tissue [1] - The clinical indication for VUM02 injection is being expanded to include the treatment of severe/critical pneumonia [1]